Publicaciones en las que colabora con Amancio Carnero (14)

2017

  1. Prognostic relevance of Src activation in stage II-III colon cancer

    Human Pathology, Vol. 67, pp. 119-125

2016

  1. Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src [Oncotarget, 7, 22, (33111-33124) (2016)] DOI: 10.18632/oncotarget.8880

    Oncotarget

  2. Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src

    Oncotarget, Vol. 7, Núm. 22, pp. 33111-33124

2015

  1. Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer

    Oncotarget, Vol. 6, Núm. 8, pp. 6151-6159

2014

  1. MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer

    BMC Cancer, Vol. 14, Núm. 1

  2. MicroRNA clusters: Dysregulation in lung adenocarcinoma and COPD

    European Respiratory Journal, Vol. 43, Núm. 6, pp. 1740-1749

  3. MicroRNA-dependent regulation of transcription in non-small cell lung cancer

    PLoS ONE, Vol. 9, Núm. 3

  4. Prognostic relevance of estrogen receptor-α Ser167 phosphorylation in stage II-III colon cancer patients

    Human Pathology, Vol. 45, Núm. 12, pp. 2437-2446

2013

  1. Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage

    International Journal of Molecular Sciences, Vol. 14, Núm. 2, pp. 3440-3455

  2. Identification of proteomic signatures associated with lung cancer and COPD

    Journal of Proteomics, Vol. 89, pp. 227-237

  3. Inhibition of HSP90 molecular chaperones: Moving into the clinic

    The Lancet Oncology, Vol. 14, Núm. 9

  4. Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma

    Clinical Cancer Research, Vol. 19, Núm. 14, pp. 3925-3935

2012

  1. PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: Incidence and implications in clinical outcome

    BMC Cancer, Vol. 12

2009

  1. Inhibiting PI3K as a therapeutic strategy against cancer

    Clinical and Translational Oncology, Vol. 11, Núm. 9, pp. 572-579